ISSN 1662-4009 (online)

ey0017.12-15 | Hyperlipidemia | ESPEYB17

12.15. Inclisiran for the treatment of heterozygous familial hypercholesterolemia

FJ Raal , D Kallend , KK, et al. Ray

To read the full abstract: N Engl J Med. 2020;382(16):1520–30. doi: 10.1056/NEJMoa1913805Short summary: Inclisiran (a small interfering double-stranded RNA against PCSK9) is superior to placebo in reducing LDL-C among individuals with heterozygous Familial Hypercholesterolemia who are already on statins and ezetimibe.Comment: Proprotein convertas...